Skip to NavigationSkip to content

Eli Lilly

NICE recommends Lilly's Emgality for chronic and episodic migraine

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on the NHS in England and Wales after NICE gave its recommendation to the drug for routine use.

The UK watchdog based its decision on data drawn from four clinical trials in which Lilly’s therapy proved twice as effective as placebo in reducing migraine headache days in patients who had already tried at least three preventative treatments, with an overall reduction of up to 40%.

US reserves 300,000 doses of Lilly's COVID-19 treatment in $375 million deal

The US Government has signed a $375 million deal with Eli Lilly to buy 300,000 700mg doses of bamlanivimab, its neutralising antibody for the treatment of COVID-19.

The therapy can be rolled out on the condition that it secures Emergency Use Authorization from the FDA. Lilly applied for this authorisation early this month in patients with mild to moderate cases of infection with the virus.

Eli Lilly refutes FDA quality concerns at New Jersey facility producing COVID-19 drug

Eli Lilly has rebutted reports of FDA quality assurance concerns at its manufacturing facility in Branchburg, New Jersey, where it is producing bamlanivimab, an experimental antibody therapy to treat COVID-19, a week after the company stopped recruiting for clinical trials of the drug.

Eli Lilly COVID-19 antibody therapy trial paused over safety concerns

Photo by Momoneymoproblemz (https://commons.wikimedia.org/wiki/File:Eli_Lilly_Corporate_Center,_Indianapolis,_Indiana,_USA.jpg)

Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns. 

The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), has so far enrolled 326 patients. Neither it, or the company, have announced what the safety issue is. 

Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations

Photo by Momoneymoproblemz (https://commons.wikimedia.org/wiki/File:Eli_Lilly_Corporate_Center,_Indianapolis,_Indiana,_USA.jpg)

Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.

Lilly's baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data

Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with COVID-19.

The study, launching on 8 May and sponsored by  the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), included over 1,000 participants in total receiving 4mg baricitinib in combination in combination with remdesivir.

Lilly and Boehringer's Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in the treatment of adults with heart failure with reduced ejection fraction, with and without diabetes.

The pair revealed that the 10mg dose of the drug met its primary endpoint in a study of 3,630 participants, successfully reducing the risk of cardiovascular death or hospitalisation as a result of heart failure when used in combination with standard of care.

Eli Lilly teams up with Chi-Med for Chinese sales of Elunate capsules

Eli Lilly Shanghai, an affiliate of the wider company, has enlisted the help of biopharma firm Hutchinson China MediTech, or Chi-Med, to commercialise its vascular endothelial growth factor receptor (VEGFR) 1/2/3 inhibitor therapy Elunate  (fruquintinib capsules) in the Chinese market, it has emerged.

The partnership kicks off in earnest from 1 October this year, from which date Chi-Med will handle all medical detailing, promotion and local and regional marketing activities related to Elunate.

Eli Lilly asks for a $24 million tax break for diabetes care facility expansion in Indianapolis

tpsdave/12019

Insulin manufacturer Eli Lilly has requested a $24 million tax break over the next 10 years as an investment into its diabetes care section.

The company itself is planning to invest $400 million in expanding its facility in Indianapolis. The expansion will create 100 new jobs and make sure 20 current jobs are retained. Michael O’Conner, the Eli Lilly Senior Director of State Government Affairs, presented this proposal to the Indianapolis City-County Council Metropolitan and Economic Development Committee this week.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches